Wall Street analysts forecast that Heat Biologics Inc (NASDAQ:HTBX) will report $1.50 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Heat Biologics’ earnings, with the lowest sales estimate coming in at $1.20 million and the highest estimate coming in at $1.80 million. The business is scheduled to report its next quarterly earnings report on Thursday, February 21st.
On average, analysts expect that Heat Biologics will report full-year sales of $5.22 million for the current year, with estimates ranging from $4.90 million to $5.54 million. For the next year, analysts expect that the firm will report sales of $4.95 million, with estimates ranging from $4.80 million to $5.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The company had revenue of $1.84 million during the quarter, compared to analysts’ expectations of $1.50 million. Heat Biologics had a negative return on equity of 94.53% and a negative net margin of 331.02%.
NASDAQ HTBX opened at $1.25 on Friday. Heat Biologics has a twelve month low of $0.95 and a twelve month high of $4.50.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp bought a new position in shares of Heat Biologics in the second quarter valued at approximately $111,000. Vanguard Group Inc. boosted its holdings in shares of Heat Biologics by 20.6% in the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after acquiring an additional 136,256 shares in the last quarter. Finally, Vanguard Group Inc boosted its holdings in shares of Heat Biologics by 20.6% in the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after acquiring an additional 136,256 shares in the last quarter. 4.46% of the stock is owned by institutional investors.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Further Reading: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.